Using time‐weighted average change from baseline of SARS‐CoV‐2 viral load to assess impact of hydroxychloroquine as postexposure prophylaxis and early treatment for COVID‐19

Two randomized controlled trials demonstrated no clinical benefit of hydroxychloroquine (HCQ) for either postexposure prophylaxis or early treatment of SARS‐CoV‐2 infection. Using data from these studies, we calculated the time‐weighted average change from baseline SARS‐CoV‐2 viral load and demonstr...

Full description

Saved in:
Bibliographic Details
Published in:Journal of medical virology 2022-12, Vol.94 (12), p.6091-6096
Main Authors: Kumbhakar, Raaka, Neradilek, Moni, Barnabas, Ruanne V., Stewart, Jenell, Stankiewicz Karita, Helen C., Landovitz, Raphael J., Kissinger, Patricia J., Jerome, Keith R., Paasche‐Orlow, Michael K., Bershteyn, Anna, Chu, Helen Y., Neuzil, Kathleen M., Greninger, Alexander L., Luk, Alfred, Wald, Anna, Brown, Elizabeth R., Johnston, Christine
Format: Article
Language:English
Subjects:
Clinical trials
COVID-19
COVID-19 - prevention & control
COVID-19 Drug Treatment
early treatment
Humans
Hydroxychloroquine
Hydroxychloroquine - therapeutic use
PEP
Prophylaxis
SARS-CoV-2
Severe acute respiratory syndrome
Severe acute respiratory syndrome coronavirus 2
Viral diseases
Viral Load
Virology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Two randomized controlled trials demonstrated no clinical benefit of hydroxychloroquine (HCQ) for either postexposure prophylaxis or early treatment of SARS‐CoV‐2 infection. Using data from these studies, we calculated the time‐weighted average change from baseline SARS‐CoV‐2 viral load and demonstrated that HCQ did not affect viral clearance.
ISSN:0146-6615
1096-9071
1096-9071
DOI:10.1002/jmv.28054